This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

PME - Pro Medicus

Jump to new

Hey Trav, if $24.70 gets taken out in the next couple of bars then we may be looking at a potential wave 3 ending at around $27.95+!
Only time will tell.
 
Well I am still hanging in there with PME, it hit a high of $27 today, only to retrace back to close @ $26.22.

Holding since November and making huge gains 3.21% but will continue to hold as I am liking the setup here. If it can break the $27 resistance the ascending triangle pattern will be confirmed.

Target would be $32 using a measure rule from http://thepatternsite.com/at.html but I will be running with a trail stop based on ATR. A few if's and but's here so we will have to watch and see how this trade pans out.

 
Yes still holding, looking good today and hopefully holds $27 and break out will be confirmed in my eyes at least.
 
Will probably get on this tomorrow, looks to have turned a corner. Reports on Thursday I believe, which should tell the story for a nice uptrend like last year, or if it needs to spend some more time going sideways.
 
This is when you wonder why you didnt buy more shares

Up 10% after interim results released.
 
Almost forgot to buy these yesterday, but remembered towards the end of the day and got in @ $27.24.
Glad I did.
 
Yes just checked closing price and pretty disappointing. Maybe a few people taking profits?

Numbers looked good at a quick glance so hopefully we resume our positive run tomorrow.
 
Weird old day for PME, I also thought the results were good.
Up almost 10% after open, then down 10% before lunch, only to come back and close just over 3% down.
Glad I also hold BRG and IEL so this didn’t ruin my day.
 
I think that a lot of stop losses got taken out. Hence that crazy drop

So maybe someone playing games.
 
Trav. said:
I think that a lot of stop losses got taken out. Hence that crazy drop

So maybe someone playing games.
Click to expand...

Closing price Thursday was $26.42 and today low of $23.76

Thursday high of $30.37 and down to today $6.61 (-27% since Thursday)

Reported ASX Thursday 13/02/2020 9:24:41 AM Half Year Accounts

Pro Medicus continued its positive form and delivered further strong revenue and profit growth in the first half of FY 2020.

For the six months ended December 31, the company posted a 15.7% increase in revenue from operations to $29.3 million.

On an underlying basis, which excludes a one-off capital sale to the German Government made in the first half of FY 2019, revenue would have grown 39.1% over the prior corresponding period.

This was driven by solid growth in all key jurisdictions. North American revenue grew 43.1%, European revenue jumped 52%, and Australian revenue lifted 21.5% during the half.

The company’s profit growth grew quicker than its revenue. Underlying profit before tax jumped 45.3% to $14.8 million and net profit after tax rose 32.7% to $12.1 million.



677
 
Another theme that Natalie Tam expects should support listed companies in the health sector. "The other big ... long-term impact of COVID-19 that we expect to see is a greater investment in healthcare globally," she says. "If you look at it globally, our capacity to deal with the crisis was very low and that has amplified the consequences of the crisis. And so we do think that there are going to be additional resources permanently devoted to the healthcare sector."

Pro Medicus is a company that draws on structural growth drivers for technology as well as health, Tam says.

It's a position Aberdeen aggressively built on following its scenario analysis of the company's income statement and balance sheet early in the crisis.
"Pro Medicus actually sits in the healthcare sector but it's probably more a medical software company – it has a pure SaaS product that is used in hospitals and for radiology clinics."
Click to expand...

Aberdeen was comfortable that the company had the earnings resilience and balance sheet to easily carry through a worst case scenario, so it started buying.
"Having done the homework when the market was in capitulation mode, we had the conviction to aggressively accumulate the stock, which is what we did."
Click to expand...

(.... another fund manager talking about their wins, as they usually do <while ignoring the losers, because deviation from index is minimal, therefore they do have 'em>)
 
COVID-19 – Impact
• All elective imaging deferred late in March/early April
• Some regions affected more than others
• Worst affected – volumes declined by up to 75%
• 2nd half April onwards – steady recovery in image volumes
• Most clients now at “near normal volumes” > 90% - some 100%
• Deferred examinations still need to be done - expectation of catchup period
 
"Yesterday, Pro Medicus shares dropped as much as 7.5% on delivering its results for FY 2020. While the record profit of $23 million was an increase of about 20% on the prior year, the second half profit was actually down on the immediately preceding half. Happily, free cash flow was very strong at $23.7m and the company finished the year with cash reserves of $43.4 million."


"The main reason for the reduced half-on-half profit was the impact of the coronavirus pandemic, which the company estimated reduced second half profit by $1.2m. Without that impact, the second half would have been mildly better than the first half, but not a lot better.

"However, there were a number of drivers of lower profit growth in FY 2020 compared to FY 2019. The biggest single reason was that the company received a $3m point in time payment for a German installation in FY 2019, and this was not repeated in FY 2020.

"Comparing the first and second halves, European and Australian revenue was largely flat, half-on-half, while the biggest hit was felt in the USA, where sales actually dropped for the first time since 2018.... "

https://arichlife.com.au/pro-medicus-asx-pme-full-year-fy-2020-results/
 
Company Announcement
Pro Medicus Limited half-year results
Wednesday 16 February 2022
HIGHLIGHTS
▪ Revenue from ordinary activities $44.33m – up 40.3%
▪ Underlying profit before tax $28.8m – up 53.5%
▪ Net profit $20.68m – up 52.7%
▪ Cash reserves $76.17m – up $14.91m
▪ Company remains debt-free
▪ Fully franked interim dividend 10c per share – up 42.9%
Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a halfyear net profit of $20.68 million for the six months to the end of December 2021, 52.7% higher
than for the previous corresponding period.
Revenue from ordinary activities increased by 40.3% to $44.33 million.
The company's cash reserves at 31 December 2021 were $76.17 million, up $14.91 million.
Pro Medicus announced a final fully franked interim dividend of 10c per share. The company
remains debt-free.
During the six months Pro Medicus announced the following key contract wins:
▪ Novant Health (A$40 million, 7-year contract), a community-based integrated delivery
network that spans three US states.
▪ Contract renewal with Allegheny Health (A$12 million, 5-year), a health network in
Pittsburgh, Pennsylvania.
▪ Further extension of German government hospital to a fourth site.
The company continued to make significant progress with all key implementations being on or
ahead of schedule, including Intermountain and UCSF.
Pro Medicus CEO Dr Sam Hupert said the result represented the strongest half-year revenue
and profit results in Pro Medicus’ history, powered by contract wins and renewals in the US
and an extension of a European contract to cover new regions.
“We thought it was a good result with all our key financial indicators heading in the right
direction, not just revenue growth but also profit growth, margin expansion and retained
earnings,” he said. “There were two key drivers behind the result. Firstly, the jump in
Pro Medicus Limited
450 Swan Street Richmond
Victoria 3121 Australia
T +61 3 9429 8800
F +61 3 9429 9455
www.promed.com.au
transaction revenue from our US contracts, as several large implementations came on-stream
towards the second half of FY21, such as Northwestern, NYU and Medstar. Secondly, the
extension of the German government contract to a fourth hospital. Renewals of contracts
should also not be underestimated; they are like a whole new contract.”
Dr Hupert said the company recorded growth in revenue in all key jurisdictions: USA, Europe
and Australia. “Our pipeline remains strong with a good spread of opportunities in different
markets. Many are Cloud-based – a trend gathering significant momentum – and many are
interested in more than one of our Visage solutions.”
Dr Hupert said the company’s operations had not been unduly affected by Covid-19.
“Exam volumes in North America were strong, and in many cases greater than pre-Covid
levels. The only region that was marginally affected was Australia, where the majority of our
revenue is not exam-based. In terms of sales capability and implementations these were not
impacted. During the half we did a mix of remote, onsite and hybrid remote/onsite
implementations.”
“Our pipeline remains strong with very healthy representations across academic, nonacademic/IDN, corporate and private market opportunities. Many are for more than one of our
products and increasingly we are seeing opportunities that have Cloud-first policy which
favours us as we believe we are the only company to have a proven, fully Cloud-native
offering that operates at scale.”
** Pro Medicus Ltd will host a webcast conference call on Wednesday 16 February at 11am
(AEDT) to discuss the results.
Authorised by the Board of Pro Medicus Limited.


------------------------------------------------------------------------------------------------------------------------------------------------------

DYOR

i hold PME ( 'free-carried' ) ( bought at 16.5 cents )

i guess if i regret selling down a winner ( sold down 95% of the original purchase ) this will be the one

but golly gee who would have picked this in 2011 to even break $10

looks like a div of more than 100% this year for me ( on my investment )

but is it really a $50 share ??

crazy times
 
Pro Medicus has reported a strong jump in profits during the first half of the 2022 financial year, buoyed by a number of key contract wins.

The company’s revenue rose 40.3 per cent to $44.3 million while net profit climbed 52.7 per cent to $20.7 million.
“We thought it was a good result with all our key financial indicators heading in the right direction, not just revenue growth but also profit growth, margin expansion and retained earnings,” said Pro Medicus chief executive Sam Hupert.
Click to expand...

Pro Medicus declared an interim dividend of 10¢, a record for the company.

............... probably more realistically priced in the $40's than the low $60s before the sell-off in January. And that last statement has got to be pretty loopy: "Renewals of contracts should also not be underestimated; they are like a whole new contract.”
 
You must log in or register to reply here.
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...